Search results for "MOTH"

showing 10 items of 2617 documents

Evaluation of low-dose metronomic (LDM) cyclophosphamide toxicity in cats with malignant neoplasia

2014

Oral administration of low-dose cyclophosphamide in pets with spontaneously occurring malignant neoplasms has become a common practice in veterinary medicine. The purpose of this retrospective study was to investigate toxicity events in cats with spontaneous malignancies receiving cyclophosphamide as a metronomic therapy for at least 1 month. The number and severity of clinical, haematological and biochemical adverse events were recorded according to the Veterinary Cooperative Oncology Group’s Common Terminology Criteria for Adverse Events v1.1 classification scheme. Twenty-four cats were enrolled in the study with a total number of 27 neoplasms: 13 sarcomas, 12 carcinomas, one melanoma an…

medicine.medical_specialtyToceranibCyclophosphamideCat DiseasesGastroenterologyDisease-Free SurvivalDrug Administration ScheduleMetastasisNeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsSmall AnimalsAdverse effectAntineoplastic Agents AlkylatingCyclophosphamideNeoplasm StagingRetrospective StudiesCATSDose-Response Relationship Drugbusiness.industryCommon Terminology Criteria for Adverse Eventsmedicine.diseaseSurgeryThalidomideToxicityCatsbusinessmedicine.drugJournal of Feline Medicine and Surgery
researchProduct

Oral complaints in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation

2021

Background Acute myeloid leukemia belongs to proliferative diseases of the hematopoietic system. It is currently the leading indication for allogeneic hematopoietic stem cell transplantation. This study was designed to determine the most common subjective oral mucosa complaints in patients with acute myeloid leukemia after allogeneic hematopoietic cell transplantation, in relation to the type of conditioning used. Material and Methods Eighty patients diagnosed with acute myeloid leukemia were assigned to two groups depending on the intensity of the conditioning regimen before transplantation: myeloablative and reduced-intensity chemotherapy. The oral symptoms were evaluated based on an auth…

medicine.medical_specialtyTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationInternal medicineMedicineHumanstumor microenvironmentdendritic cellsOral mucosaGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesChemotherapyOral Medicine and Pathologybusiness.industryResearchHematopoietic Stem Cell TransplantationMyeloid leukemiaoral cancerDysgeusiaTransplantationclec9aHaematopoiesisLeukemia Myeloid Acutemedicine.anatomical_structureOtorhinolaryngologyTaste disorderQuality of LifeSurgeryimmunotherapymedicine.symptombusiness
researchProduct

Potential Diagnostic Properties of Chest Ultrasound in Thoracic Tuberculosis-A Systematic Review.

2018

Background: Chest ultrasound (CUS) has been shown to be a sensitive and specific imaging modality for pneumothorax, pneumonia, and pleural effusions. However, the role of chest ultrasound in the diagnosis of thoracic tuberculosis (TB) is uncertain. We performed a systematic search in the medical literature to better define the potential role and value of chest ultrasound in diagnosing thoracic tuberculosis. Aim: To describe existing literature with regard to the diagnostic value of chest ultrasound in thoracic tuberculosis. Methods: MEDLINE, EMBASE, and Scopus databases were searched for relevant articles. We included studies that used chest ultrasound for the diagnosis or management of any…

medicine.medical_specialtyTuberculosisPleural effusionlow-resource settingsHealth Toxicology and MutagenesisRadiographylcsh:MedicineReview03 medical and health sciences0302 clinical medicineBiopsyMedicineHumans030212 general & internal medicinetuberculosiUltrasonographylung ultrasoundmedicine.diagnostic_testbusiness.industryUltrasoundlcsh:RPublic Health Environmental and Occupational Healthmedicine.diseasePneumonia030228 respiratory systemPneumothoraxEffusiontuberculosisRadiologybusinessInternational journal of environmental research and public health
researchProduct

Gas-containing renal stones: a red flag for renal infection.

2022

Background Gas in the renal excretory system is described as a consequence of recent procedures but it can be a sign of severe conditions such as fistulas or infections; however, gas-containing renal stones are only rarely encountered. Purpose To describe the association of gas-containing renal stones and urinary tract infection. Material and Methods We performed a retrospective evaluation of the clinical and imaging findings in a series of six patients with gas-containing renal stones and compared our findings with those of patients with gas-containing renal stones reported in the literature. Urine and stone cultures were used as a diagnostic standard for urinary tract infection. Results I…

medicine.medical_specialtyUrinary systemUrologyComputed tomographyUrineKidneyRenal infectionKidney CalculimedicineDIAGNOSTIC STANDARDHumansRadiology Nuclear Medicine and imagingRetrospective StudiesKidneyRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industrycomputed tomographyGeneral Medicinerenal stonemedicine.anatomical_structureExcretory systemKidney; computed tomography; renal stone; urinary tract infectionUrinary Tract InfectionsFLAG (chemotherapy)businessurinary tract infectionActa radiologica (Stockholm, Sweden : 1987)
researchProduct

CT and MR imaging of chemotherapy-induced hepatopathy.

2019

Chemotherapy-induced hepatopathy includes a wide variety of parenchymal and vascular hepatic changes on imaging, including diffuse or focal hepatopathies (i.e. hepatitis, steatosis, fibrosis, pseudocirrhosis, or sinusoidal obstruction). These changes can profoundly alter the hepatic parenchyma on imaging and result in both false negative and false-positive diagnoses of hepatic metastases and lead to errors in patient management strategies. It is therefore important for radiologists to have a comprehensive knowledge of the imaging patterns that may develop following chemotherapy. The purpose of this review is to explore the broad spectrum of hepatic parenchymal and vascular chemotherapy-indu…

medicine.medical_specialtyUrologymedicine.medical_treatment030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibrosisInternal medicineParenchymamedicineHumansRadiology Nuclear Medicine and imagingHepatitisChemotherapyRadiological and Ultrasound Technologymedicine.diagnostic_testChemotherapy Hepatopathy Computed tomography Magnetic resonance imaging Sinusoidal obstruction syndromebusiness.industryGastroenterologyMagnetic resonance imagingHepatologymedicine.diseaseMr imagingMagnetic Resonance Imaging030220 oncology & carcinogenesissense organsRadiologySteatosisChemical and Drug Induced Liver InjurybusinessTomography X-Ray ComputedAbdominal radiology (New York)
researchProduct

Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell…

1996

Objectives. To evaluate a selected population of 50 consecutive patients with primary T1, G3 bladder transitional cell carcinoma in the absence of carcinoma in situ (Tis) treated with a bladder-sparing approach. Methods. Between January 1983 and December 1992, all patients were treated by transurethral resection (TUR) plus adjuvant intravesical chemotherapy over 1 year. In most cases, doxorubicin, epirubicin, and mitomycin were used alone or in combination. Results. At a mean follow-up period of 52 months (range, 18 to 126), 16 of 50 patients (32%) showed a recurrent superficial tumor. The recurrent lesion was of Stage T1 in 11 (22%) cases, but was a T1, G3 tumor only in 5 cases (10%). In 2…

medicine.medical_specialtyUrologymedicine.medical_treatmentPopulationAntineoplastic AgentsMitomycinsSettore MED/24 - UrologiaCystectomyUrethraCarcinomamedicineHumansBACILLUS CALMETTE-GUERINeducationEpirubicinNeoplasm StagingCarcinoma Transitional Celleducation.field_of_studyUrinary bladderBladder cancerbusiness.industryCarcinoma in situmedicine.diseaseCombined Modality TherapyCANCERSurgeryAdministration Intravesicalmedicine.anatomical_structureTransitional cell carcinomaUrinary Bladder NeoplasmsChemotherapy AdjuvantDoxorubicinSurgical Procedures OperativeNeoplasm Recurrence LocalbusinessFollow-Up StudiesEpirubicinmedicine.drugUrology
researchProduct

ICUD-EAU International Consultation on Bladder Cancer 2012: Non–Muscle-Invasive Urothelial Carcinoma of the Bladder

2012

Item does not contain fulltext CONTEXT: Our aim was to present a summary of the Second International Consultation on Bladder Cancer recommendations on the diagnosis and treatment options for non-muscle-invasive urothelial cancer of the bladder (NMIBC) using an evidence-based approach. OBJECTIVE: To critically review the recent data on the management of NMIBC to arrive at a general consensus. EVIDENCE ACQUISITION: A detailed Medline analysis was performed for original articles addressing the treatment of NMIBC with regard to diagnosis, surgery, intravesical chemotherapy, and follow-up. Proceedings from the last 5 yr of major conferences were also searched. EVIDENCE SYNTHESIS: The major findi…

medicine.medical_specialtyUrologymedicine.medical_treatmentUrologyMEDLINEAntineoplastic AgentsContext (language use)Aetiology screening and detection [ONCOL 5]CystectomyQuality of Care [ONCOL 4]Molecular epidemiology [NCEBP 1]CystectomyTranslational research [ONCOL 3]medicineHumansNeoplasm InvasivenessProspective cohort studyNeoplasm StagingBladder cancermedicine.diagnostic_testbusiness.industryGeneral surgeryCarcinoma in situCystoscopymedicine.diseaseAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsBCG VaccineDisease ProgressionNeoplasm GradingNeoplasm Recurrence LocalUrotheliumbusinessIntravesical chemotherapyCarcinoma in SituEuropean Urology
researchProduct

Treatment of early childhood medulloblastoma by postoperative chemotherapy alone.

2005

The prognosis for young children with medulloblastoma is poor, and survivors are at high risk for cognitive deficits. We conducted a trial of the treatment of this brain tumor by intensive postoperative chemotherapy alone.After surgery, children received three cycles of intravenous chemotherapy (cyclophosphamide, vincristine, methotrexate, carboplatin, and etoposide) and intraventricular methotrexate. Treatment was terminated if a complete remission was achieved. Leukoencephalopathy and cognitive deficits were evaluated.Forty-three children were treated according to protocol. In children who had complete resection (17 patients), residual tumor (14), and macroscopic metastases (12), the five…

medicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentIntelligenceBrain tumorNeuropsychological TestsCarboplatinchemistry.chemical_compoundAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansCerebellar NeoplasmsCyclophosphamideEtoposideEtoposideProportional Hazards ModelsMedulloblastomaPostoperative CareChemotherapyAnalysis of Variancebusiness.industryDesmoplastic medulloblastomaRemission InductionInfantGeneral Medicinemedicine.diseaseSurvival AnalysisCarboplatinSurgeryMethotrexatechemistryChemotherapy AdjuvantVincristineChild PreschoolNeoplasm Recurrence Localbusinessmedicine.drugFollow-Up StudiesMedulloblastomaThe New England journal of medicine
researchProduct

CHOP Improves Response Rates but Not Overall Survival in Follicular and Mantle Cell Lymphoma (MCL)- Results of a Randomized Trial of the German Low G…

2004

Abstract In advanced stage follicular lymphoma conventional chemotherapy is non-curative and no major improvement in overall survival has been achieved by different regimens. Similarly, MCL, a lymphoma subtype with an especially poor clinical outcome, cannot be cured by conventional chemotherapy. In 1996, the German Low Grade Lymphoma Study Group (GLSG) started a randomized trial to evaluate the efficacy of two different anthracycline/anthrachinon containing regimens comparing CHOP (cyclophosphamide 750 mg/m2 day 1, vincristine 1.4 mg/m2 day 2, adriamycine 50 mg/m2 day 1, prednisone 100 mg/m2 days 1–5) and MCP (mitoxantrone 8 mg/m2 days 1–2, chlorambucil 3x3 mg/m2 days 1–5; prednisone 25 mg…

medicine.medical_specialtyVincristineImmunologyFollicular lymphomaCHOPBiochemistryGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicinemedicine030304 developmental biology0303 health sciencesMitoxantroneChlorambucilbusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimen3. Good healthLymphomaSurgery030220 oncology & carcinogenesisMantle cell lymphomabusinessmedicine.drugBlood
researchProduct

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

2012

Abstract Abstract 1632 Background: OFA is a fully human monoclonal antibody that binds to both the large and small extracellular loops of CD20. OFA is currently approved for patients (pts) with refractory chronic lymphocytic leukemia and has demonstrated activity in non-Hodgkin's lymphomas, including follicular lymphoma (FL). We previously reported results of a phase II study of OFA in combination with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg daily for 5 days) chemotherapy (O-CHOP) in pts with previously untreated FL (Czuczman et al. Br J Haematol. 2012;157:438). We now report updated efficacy, safety and pharmacokinetic (PK) follow-up…

medicine.medical_specialtyVincristineImmunologyFollicular lymphomaPhases of clinical researchCHOPOfatumumabBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternational Prognostic IndexPrednisoneInternal medicinemedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimen3. Good healthSurgerychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug
researchProduct